How much profit has ImmuCell made this year?
ImmuCell has made -5.77 M USD this year.
ImmuCell Net Income 2024
ImmuCell Net Income
-5.77 M USD
Ticker
ICCC
ISIN
US4525253062
WKN
885825
In 2024, ImmuCell's profit amounted to -5.77 M USD, a 131.91% increase from the -2.49 M USD profit recorded in the previous year.
The ImmuCell Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2023 | -5.77 |
| 2022 | -2.49 |
| 2021 | -0.08 |
| 2020 | -1.02 |
| 2019 | -1.3 |
| 2018 | -2.32 |
| 2017 | -0.17 |
| 2016 | 0.51 |
| 2015 | 1.21 |
| 2014 | -0.17 |
| 2013 | 0.12 |
| 2012 | 0.09 |
| 2011 | -0.41 |
| 2010 | -0.38 |
| 2009 | -0.22 |
| 2008 | -0.47 |
| 2007 | 0.66 |
| 2006 | 0.65 |
| 2005 | 0.71 |
| 2004 | 0.14 |
ImmuCell Revenue, EBIT, Net Income US4525253062 · 885825
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into ImmuCell, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ImmuCell from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ImmuCell’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of ImmuCell. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into ImmuCell’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing ImmuCell’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ImmuCell’s growth potential.
ImmuCell Revenue, EBIT and net profit per share
| Date | ImmuCell Revenue | ImmuCell EBIT | ImmuCell Net Income |
|---|---|---|---|
| 2023 | 17.47 M undefined | -5.75 M undefined | -5.77 M undefined |
| 2022 | 18.57 M undefined | -2.3 M undefined | -2.49 M undefined |
| 2021 | 19.24 M undefined | 260,000 undefined | -80,000 undefined |
| 2020 | 15.34 M undefined | -1.38 M undefined | -1.02 M undefined |
| 2019 | 13.72 M undefined | -950,000 undefined | -1.3 M undefined |
| 2018 | 10.99 M undefined | -2.15 M undefined | -2.32 M undefined |
| 2017 | 10.43 M undefined | -240,000 undefined | -170,000 undefined |
| 2016 | 9.54 M undefined | 890,000 undefined | 510,000 undefined |
| 2015 | 10.23 M undefined | 2.12 M undefined | 1.21 M undefined |
| 2014 | 7.6 M undefined | -210,000 undefined | -170,000 undefined |
| 2013 | 6.01 M undefined | -20,000 undefined | 120,000 undefined |
| 2012 | 5.39 M undefined | 250,000 undefined | 90,000 undefined |
| 2011 | 5.11 M undefined | -630,000 undefined | -410,000 undefined |
| 2010 | 4.39 M undefined | -690,000 undefined | -380,000 undefined |
| 2009 | 4.51 M undefined | -530,000 undefined | -220,000 undefined |
| 2008 | 4.63 M undefined | -1.17 M undefined | -470,000 undefined |
| 2007 | 6.07 M undefined | 870,000 undefined | 660,000 undefined |
| 2006 | 4.8 M undefined | 770,000 undefined | 650,000 undefined |
| 2005 | 4.98 M undefined | 940,000 undefined | 710,000 undefined |
| 2004 | 3.7 M undefined | 120,000 undefined | 140,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 3.7 M USD | 120,000 USD | 140,000 USD |
| 2005 | 4.98 M USD | 940,000 USD | 710,000 USD |
| 2006 | 4.8 M USD | 770,000 USD | 650,000 USD |
| 2007 | 6.07 M USD | 870,000 USD | 660,000 USD |
| 2008 | 4.63 M USD | -1.17 M USD | -470,000 USD |
| 2009 | 4.51 M USD | -530,000 USD | -220,000 USD |
| 2010 | 4.39 M USD | -690,000 USD | -380,000 USD |
| 2011 | 5.11 M USD | -630,000 USD | -410,000 USD |
| 2012 | 5.39 M USD | 250,000 USD | 90,000 USD |
| 2013 | 6.01 M USD | -20,000 USD | 120,000 USD |
| 2014 | 7.6 M USD | -210,000 USD | -170,000 USD |
| 2015 | 10.23 M USD | 2.12 M USD | 1.21 M USD |
| 2016 | 9.54 M USD | 890,000 USD | 510,000 USD |
| 2017 | 10.43 M USD | -240,000 USD | -170,000 USD |
| 2018 | 10.99 M USD | -2.15 M USD | -2.32 M USD |
| 2019 | 13.72 M USD | -950,000 USD | -1.3 M USD |
| 2020 | 15.34 M USD | -1.38 M USD | -1.02 M USD |
| 2021 | 19.24 M USD | 260,000 USD | -80,000 USD |
| 2022 | 18.57 M USD | -2.3 M USD | -2.49 M USD |
| 2023 | 17.47 M USD | -5.75 M USD | -5.77 M USD |
ImmuCell stock margins US4525253062 · 885825
The ImmuCell margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ImmuCell. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ImmuCell.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the ImmuCell's sales revenue. A higher gross margin percentage indicates that the ImmuCell retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the ImmuCell's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the ImmuCell's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ImmuCell's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ImmuCell. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ImmuCell's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
ImmuCell Margin History
| ImmuCell Gross margin | ImmuCell Profit margin | ImmuCell EBIT margin | ImmuCell Profit margin |
|---|---|---|---|
| 2023 | 22.15 % | -32.9 % | -33.05 % |
| 2022 | 41.2 % | -12.39 % | -13.41 % |
| 2021 | 45.01 % | 1.35 % | -0.42 % |
| 2020 | 44.72 % | -9 % | -6.65 % |
| 2019 | 49.13 % | -6.92 % | -9.48 % |
| 2018 | 47.22 % | -19.56 % | -21.11 % |
| 2017 | 50.05 % | -2.3 % | -1.63 % |
| 2016 | 56.81 % | 9.33 % | 5.35 % |
| 2015 | 61.09 % | 20.72 % | 11.83 % |
| 2014 | 58.55 % | -2.76 % | -2.24 % |
| 2013 | 50.92 % | -0.33 % | 2 % |
| 2012 | 56.59 % | 4.64 % | 1.67 % |
| 2011 | 54.99 % | -12.33 % | -8.02 % |
| 2010 | 52.39 % | -15.72 % | -8.66 % |
| 2009 | 53.22 % | -11.75 % | -4.88 % |
| 2008 | 44.71 % | -25.27 % | -10.15 % |
| 2007 | 62.6 % | 14.33 % | 10.87 % |
| 2006 | 60.83 % | 16.04 % | 13.54 % |
| 2005 | 67.27 % | 18.88 % | 14.26 % |
| 2004 | 60.81 % | 3.24 % | 3.78 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 60.81 % | 3.24 % | 3.78 % |
| 2005 | 67.27 % | 18.88 % | 14.26 % |
| 2006 | 60.83 % | 16.04 % | 13.54 % |
| 2007 | 62.6 % | 14.33 % | 10.87 % |
| 2008 | 44.71 % | -25.27 % | -10.15 % |
| 2009 | 53.22 % | -11.75 % | -4.88 % |
| 2010 | 52.39 % | -15.72 % | -8.66 % |
| 2011 | 54.99 % | -12.33 % | -8.02 % |
| 2012 | 56.59 % | 4.64 % | 1.67 % |
| 2013 | 50.92 % | -0.33 % | 2 % |
| 2014 | 58.55 % | -2.76 % | -2.24 % |
| 2015 | 61.09 % | 20.72 % | 11.83 % |
| 2016 | 56.81 % | 9.33 % | 5.35 % |
| 2017 | 50.05 % | -2.3 % | -1.63 % |
| 2018 | 47.22 % | -19.56 % | -21.11 % |
| 2019 | 49.13 % | -6.92 % | -9.48 % |
| 2020 | 44.72 % | -9 % | -6.65 % |
| 2021 | 45.01 % | 1.35 % | -0.42 % |
| 2022 | 41.2 % | -12.39 % | -13.41 % |
| 2023 | 22.15 % | -32.9 % | -33.05 % |
ImmuCell Aktienanalyse
What does ImmuCell do?
ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding ImmuCell's Profit Margins
The profit margins of ImmuCell represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of ImmuCell's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating ImmuCell's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
ImmuCell's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When ImmuCell’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about ImmuCell stock
How has the profit developed compared to last year?
The profit has increased by 131.91% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does ImmuCell publish its earnings?
ImmuCell publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of ImmuCell?
The profits of ImmuCell are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of ImmuCell?
You can learn more about the earnings of ImmuCell by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does ImmuCell pay?
Over the past 12 months, ImmuCell paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImmuCell is expected to pay a dividend of 0 USD.
What is the dividend yield of ImmuCell?
The current dividend yield of ImmuCell is .
When does ImmuCell pay dividends?
ImmuCell pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ImmuCell?
ImmuCell paid dividends every year for the past 0 years.
What is the dividend of ImmuCell?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is ImmuCell located?
ImmuCell is assigned to the 'Health' sector.
Wann musste ich die Aktien von ImmuCell kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ImmuCell from 8/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/1/2024.
When did ImmuCell pay the last dividend?
The last dividend was paid out on 8/1/2024.
What was the dividend of ImmuCell in the year 2023?
In the year 2023, ImmuCell distributed 0 USD as dividends.
In which currency does ImmuCell pay out the dividend?
The dividends of ImmuCell are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ImmuCell
Our stock analysis for ImmuCell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmuCell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
